Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Gland Pharma
Join Channel
Consolidated Standalone

Gland Pharma

₹1825.5 45.6 | 2.6%

Market Cap ₹30075 Cr.

Stock P/E 38.9

P/B 3.3

Current Price ₹1825.5

Book Value ₹ 556.8

Face Value 1

52W High ₹2221

Dividend Yield 1.1%

52W Low ₹ 1590

Edit Ratio

Gland Pharma Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Gland Pharma Ltd engages in the development, manufacture, and marketing of injectable-focused widespread liquid parental merchandise. The agency's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its merchandise below diverse therapeutic categories, which include anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, ache management, hormones and associated tablets, fertility dietary supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, breathing, blood related, ophthalmological and otological, ache/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The business enterprise additionally affords contract improvement services. It sells its products mainly under a business to business in the United States, Europe, Canada, Australia, India, and across the world. The enterprise incorporated in 1978 and is based in Hyderabad, India.

Read More..

Gland Pharma Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Gland Pharma Quarterly Results

#(Fig in Cr.) Dec 2019
Net Sales 646
Other Income 25
Total Income 671
Total Expenditure 434
Operating Profit 237
Interest 6
Depreciation 24
Exceptional Income / Expenses 0
Profit Before Tax 207
Provision for Tax 53
Profit After Tax 154
Adjustments 0
Profit After Adjustments 154
Adjusted Earnings Per Share 1

Gland Pharma Profit & Loss

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
Net Sales 991 994 1348 1479 1620 2044 2633 3463 4401 3617 4167 646
Other Income 9 30 37 34 49 86 139 135 224 240 167 25
Total Income 999 1023 1385 1513 1669 2130 2772 3598 4625 3857 4334 671
Total Expenditure 630 678 846 854 1085 1338 1678 2161 2890 2598 2759 434
Operating Profit 369 346 539 659 584 792 1095 1437 1735 1259 1575 237
Interest 13 17 16 6 4 4 7 3 5 7 8 6
Depreciation 28 57 63 74 78 82 95 99 110 147 162 24
Exceptional Income / Expenses 0 0 0 0 0 -20 0 0 0 -56 0 0
Profit Before Tax 327 272 459 578 502 686 993 1335 1619 1048 1405 207
Provision for Tax 103 63 146 164 180 234 220 338 407 273 362 53
Profit After Tax 224 209 314 414 321 452 773 997 1212 776 1043 154
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 224 209 314 414 321 452 773 997 1212 776 1043 154
Adjusted Earnings Per Share 19 13.4 20.2 26.7 20.7 29.2 49.9 60.9 73.8 47.1 63.3 1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 15% 6% 15% 15%
Operating Profit CAGR 25% 3% 15% 16%
PAT CAGR 34% 2% 18% 17%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -3% -22% NA% NA%
ROE Average 12% 14% 17% 19%
ROCE Average 17% 19% 23% 26%

Gland Pharma Balance Sheet

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Shareholder's Funds 834 1394 1677 2090 2410 2862 3646 5903 7158 7953 8995
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 92 77 57 6 5 5 4 4 4 3 3
Other Non-Current Liabilities 40 43 65 125 134 123 77 76 90 86 129
Total Current Liabilities 321 244 287 253 379 533 359 512 582 730 414
Total Liabilities 1287 1758 2086 2474 2928 3523 4086 6496 7834 8773 9541
Fixed Assets 460 649 788 872 843 929 968 954 1502 1571 1694
Other Non-Current Assets 230 254 227 194 235 236 272 419 488 314 3276
Total Current Assets 597 855 1072 1408 1851 2357 2846 5123 5844 6888 4571
Total Assets 1287 1758 2086 2474 2928 3523 4086 6496 7834 8773 9541

Gland Pharma Cash Flow

#(Fig in Cr.) Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Opening Cash & Cash Equivalents 90 76 158 273 533 373 236 169 492 311 1905
Cash Flow from Operating Activities 130 148 224 476 202 185 701 605 791 368 1136
Cash Flow from Investing Activities -190 -400 -12 -97 -359 -314 -766 -1525 -1010 1208 -2924
Cash Flow from Financing Activities 46 333 -93 -116 -4 -3 -7 1238 35 15 -7
Net Cash Inflow / Outflow -14 82 119 263 -160 -132 -72 319 -184 1591 -1795
Closing Cash & Cash Equivalent 76 158 273 533 373 236 169 492 311 1905 116

Gland Pharma Ratios

# Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Earnings Per Share (Rs) 19.04 13.35 20.24 26.7 20.72 29.16 49.88 60.95 73.78 47.11 63.34
CEPS(Rs) 21.46 16.97 24.33 31.49 25.77 34.45 55.98 66.98 80.49 56.01 73.19
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 20
Book NAV/Share(Rs) 70.9 88.96 108.23 134.87 155.56 184.71 234.25 359.3 434.87 482.8 546.04
Core EBITDA Margin(%) 36.14 31.57 37 41.9 32.97 34.55 36.28 37.61 34.33 28.16 33.8
EBIT Margin(%) 34.14 28.87 35.03 39.18 31.16 33.75 37.98 38.65 36.91 29.19 33.91
Pre Tax Margin(%) 32.8 27.2 33.82 38.75 30.91 33.58 37.71 38.55 36.79 28.99 33.73
PAT Margin (%) 22.43 20.89 23.1 27.74 19.79 22.11 29.35 28.79 27.54 21.45 25.04
Cash Profit Margin (%) 25.28 26.56 27.78 32.71 24.61 26.12 32.94 31.64 30.05 25.51 28.93
ROA(%) 20.31 13.75 16.31 18.15 11.89 14.01 20.32 18.84 16.92 9.34 11.39
ROE(%) 31.02 18.79 20.42 21.97 14.27 17.14 23.81 20.97 18.62 10.28 12.31
ROCE(%) 39.05 22.5 28.35 30.04 22.41 26.11 30.68 28 24.86 13.97 16.67
Receivable days 54.15 61.5 69.91 94.03 100.43 87.61 76.78 67.08 72.4 97.78 89.08
Inventory Days 86.69 114.35 92.53 91.25 100.26 127.19 115.61 107.06 102.05 158 140.38
Payable days 64.99 72.31 52.05 135.17 183.24 215.21 151.77 96.62 74.33 113.93 88.68
PER(x) 0 0 0 0 0 0 0 40.66 44.31 26.93 29.08
Price/Book(x) 0 0 0 0 0 0 0 6.9 7.52 2.63 3.37
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 1.09
EV/Net Sales(x) 0.11 -0.13 -0.1 -0.35 -0.4 -0.36 -0.5 10.84 11.51 4.74 6.9
EV/Core EBITDA(x) 0.3 -0.39 -0.26 -0.78 -1.11 -0.92 -1.19 26.12 29.19 13.61 18.24
Net Sales Growth(%) 28.74 0.29 35.63 9.74 9.52 26.19 28.81 31.51 27.08 -17.82 15.23
EBIT Growth(%) 54.56 -15.14 64.47 22.9 -13.47 36.43 44.95 33.82 21.37 -35 33.86
PAT Growth(%) 41.61 -6.53 49.86 31.93 -22.38 40.73 71.02 29 21.58 -36 34.48
EPS Growth(%) 41.61 -29.87 51.58 31.92 -22.38 40.73 71.02 22.19 21.05 -36.15 34.47
Debt/Equity(x) 0.21 0.12 0.07 0 0 0 0 0 0 0 0
Current Ratio(x) 1.86 3.5 3.73 5.56 4.89 4.43 7.93 10 10.04 9.43 11.04
Quick Ratio(x) 0.91 2.19 2.45 4.06 3.53 2.71 5.82 7.51 8.01 6.77 7.99
Interest Cover(x) 25.47 17.32 28.97 91.43 122.59 193.8 139.24 392.34 309.98 142.41 180.2
Total Debt/Mcap(x) 0 0 0 0 0 0 0 0 0 0 0

Gland Pharma Shareholding Pattern

# Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Promoter 57.87 57.86 57.86 57.86 57.86 57.86 57.86 57.86 51.83 51.83
FII 9.41 6.09 4.66 4.32 2.8 4.91 4.04 3.59 6.88 4.47
DII 17.37 21.91 23.13 23.24 23.38 22.45 24.17 25.23 32.83 35.37
Public 15.35 14.13 14.34 14.58 15.96 14.78 13.93 13.32 8.45 8.32
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Debtor days have improved from 113.93 to 88.68days.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 14% over the last 3 years.
  • Stock is trading at 3.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Gland Pharma News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!